打开APP

默沙东获得肺癌生物标记物IP的使用授权

  1. MolecularMD
  2. 肺癌生物标记物
  3. 默沙东

来源:生物谷 2013-08-02 09:43

2013年8月1日讯 /生物谷BIOON/ --默沙东(MolecularMD)公司获得了一种极具潜力的肺癌生物标记物intellectual property的使用授权,该生物标记物是由The Broad Institute 和 Dana-Farber Cancer Institute共同拥有的。

2013年8月1日讯 /生物谷BIOON/ --默沙东(MolecularMD)公司获得了一种极具潜力的肺癌生物标记物intellectual property的使用授权,该生物标记物是由The Broad Institute 和 Dana-Farber Cancer Institute共同拥有的。授权双方并为透露授权金额,但是MolecularMD将可以利用这种生物标记物来研究肺癌细胞中出现的DDR-2基因突变,并据此诊断肺癌并针对性开发相关药物。(生物谷Bioon.com)

详细英文报道:

MolecularMD grabbed exclusive patent rights to particularly promising lung cancer biomarker intellectual property co-owned by The Broad Institute and Dana-Farber Cancer Institute. The plan: to concoct diagnostic tests that would help match patients with targeted treatments, many of which are already FDA-approved.

Neither side is discussing financial terms, but MolecularMD, a company based in Portland, OR, gains the rights to develop diagnostic, prognostic and predictive tests involving DDR2 mutations relating to the Broad/Dana-Farber technology. MolecularMD says that the DDR2 biomarker could become the first that would enable workable drug treatments for patients with squamous cell carcinoma, the second most frequent histological subtype in patients with non-small cell lung cancer.

"DDR2 is potentially the first actionable biomarker available for [squamous cell carcinoma] patients, whose treatment options are currently limited to chemotherapy," Greg Cox, MolecularMD's director of licensing, said in a statement. He noted many could benefit from targeted therapies already approved by the FDA, and that the company is eager to start supporting clinical trials to broaden access to DDR2 diagnostics. The goal, the company noted, would be to focus on existing approved drugs but also novel compounds.

Why DDR2? As the company notes, researchers have recently discovered that squamous cell carcinoma patients have DDR2 mutations. Those mutations give rise to tumor formation, but also appear to respond to existing drugs that target kinase inhibition, the company said. And there are many already approved that would fit the bill (dasatinib, nilotinib and others) as well as more under development.

Last year, MolecularMD nailed down $6 million in Series B equity financing intended to speed up the commercial launch of various technology and tests focused on next-generation sequencing.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->